泮托拉唑与安慰剂对ICU胃肠道出血风险患者1年结局、资源使用和就业状态的影响:SUP-ICU试验的二次分析
该研究为SUP-ICU试验的二次分析,纳入3298例急性入院且有胃肠道出血风险的ICU患者,随机分配至泮托拉唑组或安慰剂组。对2099例丹麦参与者(泮托拉唑组1045例、安慰剂组1047例)利用登记数据评估1年结局。结果显示,泮托拉唑组ICU内临床重要胃肠道出血较安慰剂组低1.9个百分点(95%CI 0.3-3.5),但1年死亡率、医疗资源使用(如因胃肠道出血再入院、家庭护理和全科医生使用)、医疗费用和就业状态均无统计学显著差异。结论提示泮托拉唑减少ICU内出血但未改善1年结局。
要点
- 在ICU胃肠道出血风险患者中,泮托拉唑组ICU内临床重要胃肠道出血较安慰剂组低1.9个百分点(95%CI 0.3-3.5)。
- 1年死亡率差异为-0.013个百分点(95%CI -0.051至0.026),无统计学显著差异。
- 总医疗费用差异为€1954(95%CI -2992至6899),无统计学显著差异。
- 因胃肠道出血再入院差异为-0.005次入院(95%CI -0.016至0.005),无统计学显著差异。
- 就业状态差异为-0.178周(95%CI -0.390至0.034),无统计学显著差异。
适用人群与场景
- 急性入院且存在胃肠道出血风险的ICU患者(SUP-ICU试验人群)。
- 丹麦参与者共2099例,其中2092例有登记数据:泮托拉唑组1045例,安慰剂组1047例。
研究设计与关键结果
- 研究类型:SUP-ICU随机对照试验的二次分析;总样本量3298例急性入院ICU患者,随机分配至泮托拉唑组或安慰剂组(按中心分层);本分析纳入2099例丹麦参与者。
- 主要终点:ICU内临床重要胃肠道出血在泮托拉唑组较安慰剂组低1.9个百分点(95%CI 0.3-3.5)。
- 1年死亡率差异为-0.013个百分点(95%CI -0.051至0.026),无统计学显著差异。
- 总医疗费用差异为€1954(95%CI -2992至6899),无统计学显著差异。
- 因胃肠道出血再入院差异为-0.005次入院(95%CI -0.016至0.005),无统计学显著差异。
- 就业状态差异为-0.178周(95%CI -0.390至0.034),无统计学显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验(SUP-ICU)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ICU胃肠道出血风险患者中,泮托拉唑减少ICU内临床重要胃肠道出血,但未转化为1年死亡率、医疗资源使用或就业状态的改善(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Patients in intensive care units (ICUs) are at risk of stress-related gastrointestinal (GI) bleeding and stress ulcer prophylaxis (SUP), including proton pump inhibitors, is widely used in the attempt to prevent this. In this secondary analysis of Stress Ulcer Prophylaxis in Intensive Care Unit (SUP-ICU) trial, we assessed 1-year outcomes in the pantoprazole vs. placebo groups.
METHODS: In the SUP-ICU trial, 3298 acutely admitted ICU patients at risk of GI bleeding were randomly allocated, stratified for site, to pantoprazole or placebo. In this secondary analysis, we assessed clinically important GI bleedings in ICU and 1-year mortality, health care resource use (e.g. readmission with GI bleeding, use of home care and general practitioner), health care costs, and employment status for the Danish participants using registry data.
RESULTS: Among the 2099 Danish participants, 2092 had data in the registries; 1045 allocated to pantoprazole and 1047 to placebo. The number of clinically important GI bleedings in ICU was 1.9 percentage points [95% CI 0.3-3.5] lower in the pantoprazole group vs. the placebo group, but none of the 1-year outcomes differed statistically significantly between groups, including total health care costs (€1954 [- 2992 to 6899]), readmission with GI bleeding (- 0.005 admissions [- 0.016 to 0.005]), 1-year mortality (- 0.013 percentage points [- 0.051 to 0.026]), and employment (- 0.178 weeks [- 0.390 to 0.034]).
CONCLUSION: Among ICU patients at risk of GI bleeding, pantoprazole reduced clinically important GI bleeding in ICU, but this did not translate into a reduction in 1-year mortality, health care resource use or improvements in employment status.
参考来源
- Halling CMB, Møller MH, Marker S, et al. The effects of pantoprazole vs. placebo on 1-year outcomes, resource use and employment status in ICU patients at risk for gastrointestinal bleeding: a secondary analysis of the SUP-ICU trial. Intensive Care Med. 2022. PMID: 35122105. doi:10.1007/s00134-022-06631-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。